Detalhe da pesquisa
1.
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.
Hematol Oncol
; 38(4): 439-445, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32495944
2.
The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments.
Ann Hematol
; 99(2): 277-282, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31872362
3.
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients.
Hematol Oncol
; 35(4): 561-566, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27791277
4.
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.
Acta Haematol
; 137(1): 7-14, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-27820922
5.
Correction to: The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of pet-guided treatments.
Ann Hematol
; 100(1): 303-304, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33219839
6.
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
Br J Haematol
; 166(3): 401-9, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24761838
7.
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.
Br J Haematol
; 163(1): 40-6, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23889344
8.
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients.
Br J Haematol
; 180(4): 600-602, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27785782
9.
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
Haematologica
; 101(5): e196-9, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26858355
10.
Body composition and inflammation impact in non-small-cell lung cancer patients treated by first-line immunotherapy.
Immunotherapy
; 13(18): 1501-1519, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34670403
11.
Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapy.
Clin Nutr ESPEN
; 43: 64-75, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34024567
12.
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis.
Leuk Lymphoma
; 60(8): 1958-1964, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30689474
13.
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
Haematologica
; 93(3): 398-404, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18268277
14.
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study.
Haematologica
; 93(9): 1335-42, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18698083
15.
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.
Leuk Lymphoma
; 48(1): 56-64, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17325848
16.
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Leuk Lymphoma
; 58(3): 552-559, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27442600
17.
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.
Leuk Res
; 104: 106552, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33689920
18.
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.
Leuk Lymphoma
; 46(2): 257-63, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15621810
19.
Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.
J Breast Cancer
; 18(4): 378-85, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26770245
20.
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time.
Am J Hematol
; 84(12): 850-2, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19862827